This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Hematology				
Hemophilia	Factor IX; factor Xa	<p><i>In vitro</i> and monkey studies identified a bifunctional antibody targeting factor IX and factor Xa that could help treat hemophilia A. In human factor VIII-deficient plasma, an antibody that bound factor IX and factor Xa induced coagulation. In a monkey model of hemophilia A, the same antibody had high subcutaneous bioavailability and a long half-life and decreased bleeding compared with no treatment. Next steps include clinical testing. At least 10 companies have therapeutics targeting factor VIII to treat hemophilia in development stages ranging from clinical to marketed.</p> <p><i>SciBX</i> 5(40); doi:10.1038/scibx.2012.1053 Published online Oct. 11, 2012</p>	Findings patented; licensing status undisclosed	<p>Kitazawa, T. <i>et al. Nat. Med.</i>; published online Sept. 30, 2012; doi:10.1038/nm.2942 Contact: Takehisa Kitazawa, Fuji-Gotemba Research Laboratories, Shizuoka, Japan e-mail: kitazawatkh@chugai-pharm.co.jp</p>